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Summary A major complication of in vivo monoclonal antibody therapy in patients with cancer is the host's
immune response to the administered xenogeneic immunoglobulin. We have performed parallel clinical and
experimental studies to investigate the possibility that deaggregation of the therapeutic monoclonal antibody
might render it non-immunogenic, or even tolerogenic, as has been suggested in several animal studies.
Deaggregation of xenogeneic immunoglobulin has been shown by others to induce non-responsiveness in some
('susceptible') but not in other ('resistant') strains of mice. We have used an improved deaggregation method
of size exclusion chromatography connected to FPLC and have developed a sensitive ELISA detection system
to determine whether highly purified human immunoglobulin G (hIgG) monomers could be tolerogenic even
to 'resistant' mice. However, our data show that all preparations of hIgG are immunogenic to 'resistant' mice,
and that although deaggregation does significantly reduce the anti-hIgG response of 'susceptible' strains,
tolerance is not induced. Concommitant administration of cyclosporin A and deaggregated hIgG had a
additive effect in reducing the murine anti-hIgG secondary response. In clincial studies ofpatients with ovarian
cancer who received in vivo immunotherapy with either iodine-131 (not aggregated) or yttrium-90 (aggregated)
HMFGI mouse monoclonal antibody, no significant difference was found between the immune responses to
aggregated and non-aggregated murine immunoglobulin G. Our data suggest that deaggregation alone is
unlikely to be useful in controlling the human anti-murine immunoglobulin G response in our outbred patient
population, although in combination with an immunosuppressant it may be more effective.
Over the past decade monoclonal antibodies have made an
increasingly important contribution to the in vivo diagnosis
and treatment of cancer (Chatal et al., 1984; Carrasquillo et
al., 1986; Epenetos et al., 1987). However, despite promising
results, their clinical potential has been limited, in part, by
their immunogenicity. Most monoclonal antibodies are of
mouse or rat origin and are therefore recognised as foreign
by the human recipient (Schroff et al., 1985; Courtenay-Luck
et al., 1986). The resultant human anti-mouse immuno-
globulin (Ig) antibodies create two problems. Firstly, they
form immune complexes with the administered monoclonal
antibody and are rapidly cleared from the body, thus reduc-
ing the ability of the antibody to reach its tumour target.
Secondly, these complexes may lead to a type III hypersen-
sitivity response (serum sickness). Repeated injections of
therapeutic antibody are therefore not usually possible.
The aim of the present work was to study ways in which
the administered monoclonal antibody could be made less
immunogenic to the recipient. Experiments were performed
in animals and, where possible, parallel data were obtained
from the clinical situation. Our studies were based upon early
reports that aggregation increases immunogenicity and that
deaggregated immunoglobulin may not only be less
immunogenic but may actually be tolerogenic (Dresser,
1962). This tolerogenic effect was genetically controlled and
dependent upon the method of deaggregation used (Lukic &
Leskowitz, 1974; Golub & Weigle, 1969). We have analysed
the effects of 'antigen' deaggregation in three different strains
of mice given polyclonal human IgG, and have in addition
analysed the simultaneous effect of a well established
immunosuppressive drug, cyclosporin A. Finally, in parallel
clinical studies, the anti-mouse Ig response of patients with
ovarian cancer, who had received non-aggregated and par-
tially aggregated radiolabelled murine monoclonal antibody
for therapeutic purposes, was monitored.
Material and methods
Mice
Female BALB/c, CBA and C57BL/6 mice, 8 -10 weeks old,
were purchased from Olac Ltd, UK.
Human immunoglobulin G
Polyclonal human immunoglobulin G (hIgG) (Sigma, UK.)
was used as an immunogen for the mice. Each mouse
received 70 or 100.tg of hIgG intraperitoneally.
Deaggregation ofhuman IgG
The hIgG was purchased in lyophilised form. After recons-
titution in phosphate buffered saline pH 7.4 (PBS), it was
found to contain 20-25% aggregates. These aggregates were
pelleted by centrifugation at 150,000g for 150 min (L8-70M,
Beckman Instruments, Palo Alto, USA) and the 'deagg-
regated' contents of the top one-third of the centrifuge tube
was then removed for use as an immunogen. The presence or
absence of high molecular weight immunoglobulin aggregates
was checked by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE), silver stained, and by fast protein liquid
chromatography (FPLC) analysis (Pharmacia, Sweden). In
further experiments, monomeric hIgG was isolated by
Superose 12 and 6 (Pharmacia, Sweden) size exclusion
chromatography columns connected on to an FPLC (Figure
la, b). The monomeric fraction was used immediately after
determination of concentration, in order to avoid reaggrega-
tion. SDS-PAGE analysis showed that after deaggregation by
ultracentrifugation, a faint band at 300 kDa was visible; no
such band was seen in the fraction purified by gel filtration.
Aggregation ofhuman IgG
Human IgG was heated for 2 h at 59°C and then left over-
night on ice (Weigle, 1973). Additional aggregate formation
was confirmed by FPLC analysis (Figure lc). After deter-
mination of the protein concentration, the samples were
stored at - 20'C.
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Figure 1 FPLC profile of human IgG (hIgG): a, after deagg-
regation using Superose 6 size exclusion chromatography; b,
before deaggregation and c, after heat aggregation.
Immunisation schedule
Mice were given 70itg or 100jig of: the untreated, partially
aggregated hIgG (ag. hIgG); the monomeric, deggregated
(deag.hIgG) fraction; or the polymeric, aggregated
(heat-ag.hIgG) fraction. Human IgG was administered i.p. in
sterile PBS in a volume that never exceeded 0.8 ml. Control
mice received an equal volume of sterile PBS alone. Some
mice were killed and bled 10 days after the first injection of
hIgG (to assay their primary immune response), others were
challenged for a second time. Seven days later these animals
were bled and their secondary response against hIgG was
also measured. For each immunisation protocol, some mice
also received cyclosporin A immunosuppression (detailed
below). A minimum of three mice were used for each experi-
mental situation.
Immunosuppression with cyclosporin A
Sandimmun, containing 100 mg ml-' cyclosporin A in oil,
was obtained from Sandoz Pharmaceuticals (Switzerland).
Cyclosporin A was administered to mice orally, throughout
the immunisation period (10 days primary, 7 days secon-
dary). Mice were given either 7 or 15 mg kg-' mouse-' daily.
Control mice received vehicle (oil) alone.
Patients
Twenty-two patients with carcinoma of the ovary were given
radiolabelled monoclonal antibody HMFG1 as part of their
antitumour therapy. Patients received approximately 15 mg
of radiolabelled antibody i.p. via a small catheter into the
abdomen. A serum sample was taken before and 14 days
after treatment.
Monoclonal antibody HMFGJ
HMFGI is a mouse IgGl monoclonal antibody that recog-
nises a large mucin-like molecule normally produced by the
lactating breast, but also expressed by the majority (> 90%)
of ovarian, breast and other cancers of epithelial origin
(Taylor-Papadimitriou et al., 1981). HMFG1 was
radiolabelled with either iodine-131 (Amersham Interna-
tional, UK) using the N-bromo-succinamide (Sigma) method
(Reay, 1982), or with yttrium-90 (AERE, Harwell, UK).
Before yttrium-90 labelling, the antibody was conjugated to
diethylenetriamine penta-acetic acid (DTPA) (Sigma) by the
cyclic anhydrate method (Hnatowitch et al., 1983). Yttrium-
90 was then coupled to the antibody using a method based
on that established for indium-ill (Hnatowitch et al., 1983;
Paik et al., 1985).
Assessment ofaggregation oftherapeutic monoclonal antibody
preparations
FPLC analysis and autoradiography of the HMFG1 before
and 24 h after (serum sample) administration to the patients
revealed that it was monomeric and that it remained
monomeric after labelling with iodine-131 (Figure 2a). In
contrast, yttrium-90-labelled HMFG1 was found to be par-
tially aggregated (up to 40%) due to antibody cross-linkage
via the bifunctional DTPA reagent (Figure 2b).
a
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Figure 2 FPLC profile of the mouse monoclonal antibody
HMFGI when labelled with: a, iodine-131; and b, yttrium-90.
Measurement ofthe anti-immunoglobulin response
All blood samples were left to clot overnight at 4°C. They
were then centrifuged and the supernatant serum removed,
aliquoted and stored at - 20°C. An enzyme-linked immun-
sorbent assay (ELISA) was used to measure the anti-Ig res-
ponse. This has been described in detail elsewhere
(Courtenay-Luck et al., 1986). Briefly, 5figml1' of either
hIgG (to assay mouse sera) or HMFG1 (to assay patients'
sera) was coated on to 96-well plates (Sterilin, UK) for 3 h at
37TC in bicarbonate buffer pH 9.6. After three washes with
PBS containing 0.02% Tween 20 (Sigma) plates were
incubated for 2 h at 37°C with serial 1:10 dilutions of test
mouse or human sera, as appropriate. The plates were then
washed with PBS/Tween as before, and a peroxidase-
conjugated, species specific sheep anti-mouse Ig (mouse test
sera) or species specific sheep anti-human Ig (human test
sera) was applied (Amersham International). After incuba-
tion for 1 h at 37°C, the plates were washed as before and the
substrate 2,2'-azino-di-[3-ethylbenzthiazolinesulphonate]
(ABTS; Behring, FR Germany) was added. The development
of colour in each well was measured by determining the
absorbence at 405 nm using a Titertec multiscanner (Flow
Laboratories, UK). All groups of sera were tested
independently as well as pooled together. All data shown are
from grouped sera. Where three sera for a group were not
available, the data are shown as not tested (n.t.). Where a
comparison between two or more ELISA plates was neces-
sary, at least two appropriate reference sera were used. Data
given are the absorbence values for serum samples diluted
either 1:10 (Figures 3a and 5b, d, f) or 1:100 where there was
a prozone effect at 1:10. Statistical analysis was performed
using Student's t test. This was only used to compare dataDEAGGREGATION AND ANTI-XENOGENEIC Ig RESPONSE 513
within, and not between, experiments. Each histogram pres-
ented represents a single experiment.
Results
Immune response to hIgG in BALBIc mice: effect of
deaggregation by ultracentrifugation
BALB/c mice were given 70jig of polyclonal human IgG (in
0.8 ml sterile PBS) that was either untreated or had been
deaggregated by ultracentrifugation, and the primary
(10 days) response was measured. Control mice received
0.8 ml sterile PBS alone. A small difference was seen in the
response of BALB/c mice to these hIgG preparations (Figure
3a, P =0.01).
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Figure 3 a, Primary response of BALB/c mice to aggregated
(ag.hIgG) and ultracentrifuge deaggregated (deag.hIgG) hIgG.
Primary (b) and secondary (c) responses of BALB/c mice to
aggregated (ag.), heat aggregated (heat-ag.) and chromatog-
raphically deaggregated (deag.) hIgG. All responses were
measured by ELISA. The vertical axis shows absorbance at
405 nm. deag.X deag: primary immunization with deag.hIgG;
secondary with deag.hIgG. deag.X ag.: primary immunization
with deag.hIgG; secondary with ag.hIgG. ag.Xdeag.: primary
immunization with ag.hIgG; secondary with deag.hIgG. ag.X ag.:
primary immunization with ag.hIgG; secondary with ag.hIgG.
Immune response to hIgG in BALB/c mice: effect of
deaggregation by size exclusion chromatography
BALB/c mice were given 100 Ig of one of the following hIgG
preparations (in 0.2 ml sterile PBS): untreated; deaggregated
by Superose 12 size exclusion chromatography connected to
an FPLC; or heat aggregated. Negative control mice received
only 0.2 ml sterile PBS. The primary (10 day) immune res-
ponse to these different immunogens is shown in Figure 3b.
The untreated (ag.hIgG) and heat aggregated (heat-ag.hIgG)
preparations were equally immunogenic. However, mice
immunised with chromatographically deaggregated hIgG
(deag.hIgG) showed a highly significant lowering of the
immune response, in comparison to either ag.hIgG
(P = 0.0005) or the heat-ag.hIgG (P = 0.001). Subsequently,
all these groups were rechallenged with a further 100Ig of
either deag.hIgG or ag.hIgG in all possible combinations of
primary and secondary antigen. When tested 7 days later
(secondary response) all groups that received at least one
deag.hIgG immunisation were found to have responded
significantly less than those that received two doses of
ag.hIgG (Figure 3c). The P values were 0.001 for ag.Xag. vs
ag.Xdeag., 0.0021 for ag.Xag vs deag.Xag., and 0.001 for
ag.Xag. vs deag.Xdeag.
Immune response ofCBA and C57 BL/6 mice to human IgG:
effects ofdeaggregation using size exclusion chromatography
One hundred jig of ag.hIgG, deag.hIgG or heat-ag.hIgG
(0.2 ml in sterile PBS) was administered i.p. to CBA and
C57BL/6 mice. The deag.hIgG was deaggregated using a
Superose 6 size exclusion chromatography column connected
to an FLPC. Control mice received 0.2 ml sterile PBS. The
primary response to ag.hIgG and heat-ag.hIgG was high in
CBA and C57BL/6 mice. In contrast, the response to
deag.hIgG was very low in both strains of mice (Figure 4a,c),
with P <0.008 in all cases. On day 10 all groups were
rechallenged with a further 100pg of either deag.hIgG or
ag.hIgG, and the secondary response was assayed 7 days
later. All groups of mice showed a secondary response,
although this varied in magnitude according to the
immunisation schedule and the strain of mouse used (Figure
4b, d). In C57/BL6 mice the immune response was reduced
when at least one injection was of the deaggregated material,
either primary or secondary (Figure 4d, P<0.05). In con-
trast, for CBA mice, only those receiving deaggregated hIgG
for both primary and secondary injections, showed a
significantly reduced immune response (Figure 4b, P<0.05).
Immune response to hIgG in BALBIc mice: effect of
deaggregation by size exclusion chromatography in
combination with cyclosporin A immunosuppression
Human IgG was deaggregated by isolating the peak that
corresponded to approximately 150 kDa using a Superose 6
size exclusion chromatography column connected to an
FPLC (Figure la). BALB/c mice were immunised i.p. with
100jig (in 0.2 ml sterile PBS) of either the untreated or the
chromatographically deaggregated hIgG, or with PBS alone,
and their primary response measured at day 10. Mice from
each group were then boosted with a further 100jig of either
ag.hIgG or deag.IgG, and their secondary response assayed
after 7 days. Throughout the 10-day primary immunisation
period half the mice in each group received a daily oral dose
of either 7 or 15 mg kg-' day-' cyclosporin A. Control mice
received an equal volume of oil alone. The primary responses
of these mice are summarised in Figure 5a, b. In contrast to
the previous experiment, the mice responded equally well to
both ag.hIgG and deag.hIgG. Cyclosporin A at 7 and
15 mg kg-' day-' reduced this primary response (Figure 5a,
b), with P <0.0085. Those mice that were to be assayed for
the secondary response received cyclosporin A for the 7-day
secondary immunisation period only. The data for the secon-
dary response, assayed on day 17, are given in Figure Sc-f.
As before, 15 mg kg-' day-' was sufficient to significantly
f
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Figure 4 Primary (a) and secondary (b) responses of CBA mice to aggregated (ag.hIgG), heat aggregated (heat-ag.hIgG) and
chromatographically deaggregated hIgG (deag.hIgG). Primary (c) and secondary (d) responses ofC57BL/6 mice to aggregated, heat
aggregated and chromatographically deaggregated hIgG. All responses were measured by ELISA. The vertical axis shows
absorbance at 405 nm. deag.X deag.: primary immunisation with deag.hIgG; secondary with deag.hIgG. deag.Xag.: primary
immunisation with deag.hIgG; secondary with ag.hIgG. ag.X deag.: primary immunisation with ag.hIgG; secondary with
deag.hIgG. ag.X ag.: primary immunisation with ag.higG; secondary with ag.hIgG.
reduce the mouse anti-hIgG response (Figure 5c, e;
P<0.002), and we observed an additive effect with cyclos-
porin A and deag.hIgG (Figure 5c). Cyclosporin A at
7mgkg-'day-' was insufficient to give immunosupression
(Figure 5d, f) in all situations except that where the animals
were both primed and boosted with deag.hIgG (Figure Sd;
P = 0.001).
Immune response ofpatients with cancer to therapeutic mouse
IgG monoclonal antibody: effect ofdeaggregation
Twenty-two patients with ovarian cancer were given approx-
imately 15 mg monoclonal antibody HMFG1 intraperi-
toneally, for therapeutic purposes. Eleven received antibody
labelled with iodine-131 (80-150mCi), while the other 11
received antibody labelled with yttrium-90 (5-20mCi). All
patients were receiving monoclonal antibody treatment for
the first time. Each patient's anti-mouse IgG response was
measured before and 14 days after therapy. The iodine-131
labelled monoclonal antibody was monomeric (Figure 2a),
but the yttrium-90 labelled antibody contained up to 40%
aggregates (Figure 2b), due to the DTPA coupling procedure.
No significant difference was observed between the anti-
mouse IgG response of these two groups (Figure 6).
Discussion
One of the major problems that has to be overcome before
monoclonal antibody therapy for cancer can reach its full
potential is the immunogenicity of the administered
xenogeneic immunoglobulin. Since 1962 when Dresser first
reported that he could induce tolerance to bovine gamma-
globulin many investigators have supported the view that
deaggregated IgG is tolerogenic in some strains of mice
('susceptible') but not in others ('resistant') (Golub & Weigle,
1969; Lukic et al., 1975a, b; Pepys & Taussig, 1974) The
work presented in this paper was designed to investigate the
possibility that deaggregation of the monoclonal antibodies
used for in vivo therapy might render them tolerogenic to the
recipient. We used two approaches. Firstly, we used a
genetically 'inverted' experimental model in which we studied
the immune response of mice to various preparations of
human IgG to determine whether more stringent deaggrega-
tion could render IgG tolerogenic even to a 'resistant'
animal. Secondly, we studied the immune responses of a
series of patients with cancer to therapeutic mouse monoc-
lonal antibody that was coupled with either iodine-131 (no
aggregates) or yttrium-90 (contains aggregates).
The degree of deaggregation appears to be crucial in
obtaining pure tolerogenic Ig monomers. In previous studies,
careful deaggregation using Na2SO4 fractionation or
biological filtration (Golub & Weigle, 1969; Lukic et al.,
1975b) was found to be more effective than ultracentrifuga-
tion (Dresser, 1962; Pepys & Taussig, 1974; Lukic et al.,
1975b; Das & Leskowitz, 1970; Benjamin et al., 1986) for
producing tolerogenic Ig. For this study we chose to deagg-
regate our IgG using FPLC gel filtration since this provides a
rapid and highly efficient (>90% monomeric fraction
recovered) method of deaggregation. A second important
consideration is the method by which the anti-Ig response is
detected. The main system used by previous investigators was
the rate of biological clearance of iodine-125-labelled gamma-
globulin (Golub & Weigle, 1969; Pepys & Taussig, 1974;
Lukic et al., 1975b). For the experiments presented here we
have developed a highly sensitive ELISA to quantitate the
anti-xenogeneic Ig response.
The induction of tolerance in mice to deaggregated IgG
appears to be under genetic control. Thus, strains such as
C57BL/6, A/J, DBA/2, CBA and C3H/HE mice have been
shown to be 'susceptible' to the induction of unrespon-
siveness (Golub & Weigle, 1969; Lukic et al., 1975b; Fujiwara
& Cinader, 1974; Staples et al., 1970), whereas BALB/c, SJL,
NZB and DDD mice are particularly 'resistant' (Golub &
Weigle, 1969; Lukic et al., 1975a; Staples et al., 1970;
Hosono et al., 1977; Playfair, 1971; Hosono & Fujiwara,
1979a, b). Our data support these findings to some extent,
showing that while BALB/c are high responders, C57BL/6
and CBA are low responders to hIgG.
A comparison of the immune response that was generated
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Figure 5 Primary response of BALB/c mice to aggregated (ag.) and chromatographically deaggregated (deag.) hIgG, when
15 mgkg-' day-' (a) or 7 mgkg-' day-' (b) cyclosporin A (CSA) was orally administered. Secondary response of BALB/c mice to
aggregated and deaggregated hIgG, when 15 mgkg-' day-' (c,e) or 7 mg kg-' day-' (d, f) cyclosporin A was orally administered.
The response is measured by ELISA. The vertical axis shows absorbence at 405nm. deag.X[deag. + CSA]: primary immunisation
with deag.hIgG; secondary with deag.hIgG in combination with CSA. deag.X[ag. + CSA]: primary immunisation with deag.hlgG;
secondary with ag.hIgG in combination with CSA. ag.X[deag. + CSA]: primary immunisation with ag.hlgG; secondary with
deag.hIgG in combination with CSA. ag.X[ag. + CSA]: primary immunisation with ag.hlgG; secondary with ag.hIgG in combina-
tion with CSA. deag.X deag: primary immunisation with deag.hIgG; secondary with deag.hIgG. deag.Xag.: primary immunisation
with deag.hIgG; secondary with ag.hIgG. ag.X deag.: primary immunisation with ag.hlgG; secondary with deag.hIgG. ag.Xag.:
primary immunisation with ag.hIgG; secondary with ag.hIgG.
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Figure 6 Anti-mouse Ig response of patients with cancer, who
received either the deaggregated iodine-131 or the aggregated
yttrium-90 labelled murine monoclonal antibody HMFGI. The
levels were measured before (pre) and 14 days after (post) the
therapeutic administration of the monoclonal antibody, by
ELISA. Absorbence at 405nm is shown on the vertical axis.
to either aggregated or deaggregated hIgG prepared by
FPLC showed that the chromatographically prepared
monomers induced a smaller anti-hIgG response in both
'responder' and 'non-responder' strains of mice, although the
level of reduction was less and more variable in the 'res-
ponder' BALB/c strain (ranging from 65% reduction, Figure
3b to no effect, Figure 5a, b). The data therefore indicate
that deaggregation leads to a reduction in immunogenicity,
but we have no evidence for the induction of tolerance.
Cyclosporin A reduces the primary and secondary B-cell
immune responses, to both immunoglobulin preparations,
presumably via its well known inhibitory action of T-cell
activation and lymphokine secretion (Bickel et al., 1987;
Krusemeier & Snow, 1988; Borel et al., 1977). Additional
experiments showed that the secondary immune response to
deaggregated hIgG, in combination with CSA, resulted in a
depression of the immune response, that was greater than
that achieved with either factor alone. Similar co-operative
effects between CSA and deaggregation have recently been
described in rabbits given murine monoclonal antibody
(Ledermann et al., 1988).
Parallel studies on the effects of Ig aggregation were car-516 G.B. SIVOLAPENKO et al.
ried out in 22 patients with cancer, who were receiving
immunotherapy, where we could compare the immune res-
ponse generated to non-aggregated (iodine-131 labelled) and
aggregated (yttrium-90 labelled) mouse monoclonal antibody.
However, in this situation both preparations were found to
be equally immunogenic (Figure 6), despite the fact that the
non-aggregated iodine-131 preparation was composed of
pure monomers, as shown by FPLC (Figure 2) or SDS-
PAGE analysis. These findings can probably be attributed to
the fact that genetically controlled immune response
differences would be difficult to see in the outbred human
population.
Alternatively, it is possible that we are underestimating the
immune response to aggregated murine Ig since yttrium-90-
labelled monoclonal antibodies result in higher bone marrow
toxicity (and hence immunosuppression) than those labelled
with iodine-131 (unpublished observations). A further con-
tributory factor in our inability to induce tolerance to
monomeric murine Ig in patients may be the fact that the
therapeutic antibody has specificity for a cell surface antigen,
since such reagents are less tolerogenic than those that either
bind to soluble antigen or have no specific target antigen in
the treated recipient (as is the case with our mice given
polyclonal hIgG) (Benjamin et al., 1986).
The route ofadministration is also thought to influence the
ability to induce suppression of an immune response. Suc-
cessful tolerance has been achieved with both intravenious
(i.v.) and intraperitoneal (i.p.) routes (Golub & Weigle, 1969;
Pepys & Taussig, 1974; Lukic et al., 1975b). We selected i.p.
administration for our studies since this is the regional
administration route used to optimise the localisation of
therapeutic antibodies in our patients with ovarian cancer
(Epenetos et al., 1987). It is possible that an i.v. route might
be more effective in generating immune unresponsiveness in
these patients.
Our studies indicate that deaggregation alone is not
sufficient to abrogate the human anti-mouse Ig response in
patients with cancer undergoing monoclonal antibody
therapy. The concommitant use of deaggregated immuno-
globulin and cyclosporin A immunosuppression might be
expected to have an additive effect in reducing the immune
response, although the bone marrow toxicity and generalised
immunosuppression resulting from cyclosporin A therapy
make this approach less attractive. Our goal must therefore
still remain the induction of tolerance that is antigen-specific,
leaving the rest of the immune system intact.
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